BioMarin Pharmaceutical Inc.
BMRN
$62.32
-$5.16-7.65%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 513.22% | 162.72% | 91.25% | 74.35% | 8,282.73% |
| Total Depreciation and Amortization | -12.11% | -26.00% | 4.11% | 3.52% | 9.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.41% | 93.27% | 1.45% | -44.46% | 1,868.70% |
| Change in Net Operating Assets | 14.38% | -2.15% | -6.73% | 51.35% | -638.86% |
| Cash from Operations | 575.42% | 63.28% | 69.51% | 163.53% | 305.00% |
| Capital Expenditure | 32.46% | 15.05% | 1.19% | -6.74% | 18.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 366.14% | 109.58% | 118.74% | 313.61% | -89.50% |
| Cash from Investing | 217.61% | 64.72% | 206.40% | 52.57% | -18.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -30,370.76% | 97.10% | 95.86% | -- |
| Issuance of Common Stock | -46.90% | 10.15% | 1.37% | -66.00% | -41.87% |
| Repurchase of Common Stock | -25.23% | -30.31% | -2.14% | 2.87% | -9.28% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -108.89% | -37.57% | -- | -- | 99.55% |
| Cash from Financing | -73.63% | -63,240.74% | 5.43% | -5.03% | -0.27% |
| Foreign Exchange rate Adjustments | 168.66% | -246.96% | 19.91% | 741.48% | -5,236.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 982.87% | -425.93% | 96.97% | 94.37% | 18.11% |
